VYGR
USDVoyager Therapeutics Inc. Common Stock
वास्तविक समय मूल्य
मूल्य चार्ट
मुख्य मीट्रिक्स
बाजार मीट्रिक्स
खुलना
$4.230
उच्च
$4.380
कम
$4.201
मात्रा
0.47M
कंपनी के मौलिक सिद्धांत
बाजार पूंजीकरण
233.5M
उद्योग
जैव प्रौद्योगिकी
देश
United States
ट्रेडिंग आँकड़े
औसत मात्रा
0.70M
एक्सचेंज
NMS
मुद्रा
USD
52-सप्ताह रेंज
AI विश्लेषण रिपोर्ट
अंतिम अपडेट: 31 अक्टू॰ 2025Voyager Therapeutics (VYGR): AI Signals 4.25% Upsurge Potential Amid Biotech Innovation Push and Bullish Reversal Indicators
Price Action: Volatility With Emerging Strength
- Recent Trajectory: After bottoming at $2.65 in August, shares climbed to $5.41 by October 8th, then pulled back to $4.52 by October 30th. Friday's close at $4.67 suggests a potential reversal.
- Technical Mixed Signals: MACD's bullish crossover (now at -0.0131 vs signal -0.0136) conflicts with DMI's bearish trend (ADX: 20.9, -DI stronger than +DI). Short-term buyers could test $4.89 resistance.
- Volume Insights: October 8th’s sharp spike to $5.41 occurred on 1.66M shares (220% above average), signaling sudden institutional interest. Recent volumes (Oct 27-31) dropped below average, hinting at consolidation.
News Catalysts: Analyst Tailwinds vs Developmental Risks
- Bullish Update: HC Wainwright reaffirmed a Buy rating with a $30 price target (645% above current price) on September 15th, highlighting Alzheimer’s pipeline progress.
- Market Skepticism: Despite analyst optimism, fundamentals show:
- Revenue contraction (-82.4%)
- Negative ROE (-37.3%)
- Sky-high debt-to-equity (16.48 vs threshold 0.70)
- Sector Risk: Small cap biotech ($259M market cap) stocks often hinge on binary events like trial results--sudden moves possible.
AI Projections:
संबंधित समाचार
Voyager Reports Third Quarter 2025 Financial and Operating Results
- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular
AI भविष्यवाणीBeta
AI सिफारिश
पर अपडेट किया गया: 10 नव॰ 2025, 05:34 pm
66.8% आत्मविश्वास
जोखिम और ट्रेडिंग
प्रवेश बिंदु
$4.22
लाभ लें
$4.31
स्टॉप लॉस
$3.81
मुख्य कारक
संबंधित स्टॉक
अपडेट रहें
मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।